newsfilter
← Latest News
Business Wire·

Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Completed pivotal trial of BT-001 for type 2 diabetes and reported positive secondary endpoint results after 180 days of treatment On track to submit de novo classification request for BT-001 with FDA in third quarter of 2022 Completed enrollment